JSPR - Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting | Benzinga
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.
Details of the presentations are as follows:
Abstract Title: Briquilimab, An Anti-CD117 Antibody, Prevents Passive Systemic Anaphylaxis in Mice Expressing Chimeric Human and Mouse CD117 Through Mast Cell Depletion
Poster Number: 024
Session Title: Therapeutic Trials in Allergic Skin Disorders and Anaphylaxis 2024
Session Type: Poster Session
Session Date / Time: Friday, February 23, 2024; 3:15 p.m. - 4:15 p.m. EST
Abstract Title: Briquilimab, an Anti-CD117 Antibody, Prevents Cockroach Allergen Induced Allergic Asthma in Mice Expressing Chimeric Human and Mouse CD117
Publication Number: 441
Session Title: Old Therapeutics and New Targets in Asthma
Session Type: Oral Abstract Session
Session Date / Time: Saturday, February 24, 2024; 2:00 p.m. - 3:15 p.m. EST
Abstract Title: Amelioration Of Mrgprb2-Mediated Anaphylactoid Drug Reactions With Briquilimab, An Anti-CD117 Antibody, Through Mast Cell Depletion In Mice Expressing Chimeric Human And Mouse CD117
Poster Number: 747
Session Title: Around the Horn: Dermatology, Drug Allergy, Anaphylaxis, Insect Hypersensitivity
Session Type: Featured Poster Session
Session Date / Time: Sunday, February 25, 2024; 4:45 p.m. - 6:15 p.m. EST
About Briquilimab
Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such ...